10th Jan 2019 09:59
LONDON (Alliance News) - hVIVO PLC on Thursday said it achieved the primary endpoint in a phase II study of FLU-v, a vaccine candidate for influenza.
The company said that the study showed that the treatment led to a "statistically significant" reduction in mild to moderate influenza, most commonly known as flu.
If compared to placebo, one dose of FLU-v produced a highly statistically significant reduction in the disease, the company explained, comprising a positive signal of influenza infection and at least one influenza symptom.
"These results together with the previously reported highly statistically significant reduction in symptoms endpoint and performing better than placebo in a number of other key endpoints is evidence of the vaccine's protective effect," hVIVO said.
hVIVO shares were trading 10% higher at 31.45 pence each following the news.
Related Shares:
hVIVO